Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atriplex canescens pollen is an allergenic extract derived from the pollen of the *Atriplex canescens* plant, commonly known as fourwing saltbush, scale, or wing shad. It is used for the diagnosis and treatment of allergic diseases such as hay fever and allergic rhinitis. As a diagnostic tool, it is used in skin testing to identify sensitivity to the allergen. As a therapeutic agent, it is used in allergen immunotherapy (desensitization) to reduce the patient's allergic response over time. The product is a non-standardized biologic extract administered via percutaneous or subcutaneous injection and has been approved in the United States since 1941.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atriplex canescens pollen.